Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Arbutus Biopharma	Galera Therapeutics	Ampio Pharmaceuticals	Kamada	Nabriva Therapeutics
Symbol	NASDAQ:ABUS	NASDAQ:GRTX	NYSEAMERICAN:AMPE	NASDAQ:KMDA	NASDAQ:NBRV
Price Information
Current Price	$3.30	$8.06	$1.82	$6.14	$1.66
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.4	1.6	1.3	1.4	1.3
Analysis Score	3.4	3.5	3.5	3.5	3.3
Community Score	2.8	2.1	2.5	2.2	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	1.7	0.0	0.0	0.0
Earnings & Valuation Score	0.6	0.6	0.6	1.3	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Hold
Consensus Price Target	$6.50	$17.00	$4.00	$11.00	$6.00
% Upside from Price Target	96.97% upside	110.92% upside	119.78% upside	79.15% upside	261.45% upside
Trade Information
Market Cap	$315.43 million	$201.31 million	$356.05 million	$273.35 million	$415.41 million
Beta	3.15	1.89	1.79	1.1	1.91
Average Volume	2,523,287	66,521	3,571,602	212,729	2,118,854
Sales & Book Value
Annual Revenue	$6.01 million	N/A	N/A	$127.19 million	$9.48 million
Price / Sales	52.48	N/A	N/A	2.15	43.82
Cashflow	N/A	N/A	N/A	$0.52 per share	N/A
Price / Cash	N/A	N/A	N/A	11.74	N/A
Book Value	($1.00) per share	$2.81 per share	$0.04 per share	$3.04 per share	$0.44 per share
Price / Book	-3.30	N/A	N/A	2.02	3.77
Profitability
Net Income	$-153,720,000.00	$-51,930,000.00	$-13,630,000.00	$22.25 million	$-82,760,000.00
EPS	($1.62)	($16.31)	($0.14)	$0.55	($11.20)
Trailing P/E Ratio	N/A	N/A	N/A	12.79	N/A
Forward P/E Ratio	N/A	N/A	N/A	55.82	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-1,163.48%	N/A	N/A	15.60%	-1,682.55%
Return on Equity (ROE)	N/A	-151.01%	-192.88%	12.89%	-129.80%
Return on Assets (ROA)	-59.66%	-60.72%	-97.89%	10.66%	-71.67%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	N/A	0.21%
Current Ratio	15.94%	8.79%	5.65%	7.52%	4.95%
Quick Ratio	15.94%	8.79%	5.65%	5.69%	4.42%
Ownership Information
Institutional Ownership Percentage	28.44%	75.41%	9.91%	14.25%	23.70%
Insider Ownership Percentage	6.70%	19.30%	3.60%	N/A	2.76%
Miscellaneous
Employees	76	32	23	408	162
Shares Outstanding	95.58 million	24.98 million	195.63 million	44.52 million	250.25 million
Next Earnings Date	5/10/2021 (Estimated)	5/11/2021 (Estimated)	5/5/2021 (Estimated)	5/17/2021 (Estimated)	5/10/2021 (Estimated)
Optionable	Optionable	Not Optionable	Optionable	Not Optionable	Optionable

Source	Headline
	Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for IPF finance.yahoo.com - April 9 at 11:11 AM
	Brokerages Expect Nabriva Therapeutics plc (NASDAQ:NBRV) Will Post Quarterly Sales of $1.46 Million americanbankingnews.com - April 8 at 1:12 AM
	Nabriva Therapeutics plc (NASDAQ:NBRV) Expected to Announce Earnings of -$0.57 Per Share americanbankingnews.com - April 7 at 12:08 AM
	Nabriva Therapeutics plc (NASDAQ:NBRV) Short Interest Update americanbankingnews.com - April 1 at 3:20 PM
	Nabriva Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference finance.yahoo.com - April 1 at 12:27 PM
	Nabriva Therapeutics plc (NASDAQ:NBRV) Stock: Up 19.08% Since Low, This Stock Is Just Getting Warmed Up stocksregister.com - March 29 at 8:12 AM
	Nabriva Therapeutics plc (NASDAQ:NBRV) Has Recovered 16.02% So Far, But Another 562.98% Gain Cannot Be Ruled Out marketingsentinel.com - March 26 at 2:34 PM
	Nabriva Therapeutics plc (NASDAQ:NBRV) Expected to Post Quarterly Sales of $1.46 Million americanbankingnews.com - March 22 at 1:48 AM
	-$0.63 EPS Expected for Nabriva Therapeutics plc (NASDAQ:NBRV) This Quarter americanbankingnews.com - March 20 at 4:08 PM
	Nabriva Therapeutics (NASDAQ:NBRV) Shares Gap Up to $1.92 americanbankingnews.com - March 17 at 10:51 AM
	NBRV Stock Price Increases Over 15% Pre-Market: Why It Happened pulse2.com - March 17 at 8:44 AM
	Nabriva Therapeutics (NASDAQ:NBRV) Shares Down 8.6% americanbankingnews.com - March 16 at 7:56 PM
	Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient Management of Community Acquired Bacterial Pneumonia (CABP) with Oral XENLETA® (lefamulin) finance.yahoo.com - March 16 at 12:16 PM
	Nabriva Therapeutics PLC (NBRV) CEO Theodore Schroeder on Q4 2020 Results - Earnings Call Transcript seekingalpha.com - March 13 at 3:58 PM
	Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides ... apnews.com - March 12 at 7:55 PM
	Northland Securities Trims Nabriva Therapeutics (NASDAQ:NBRV) Target Price to $6.00 marketbeat.com - March 12 at 8:19 AM
	Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March ... apnews.com - March 4 at 9:56 AM
	Nabriva Therapeutics plans to raise $25.4M through stock sale bizjournals.com - March 4 at 12:26 AM
	Why Nabriva Therapeutics's Stock is Trading Lower Today msn.com - March 1 at 1:26 PM
	Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market ... apnews.com - March 1 at 8:25 AM
	Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules finance.yahoo.com - March 1 at 8:25 AM
	Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer finance.yahoo.com - February 26 at 11:19 AM
	Nabriva Therapeutics announces CFO retirement seekingalpha.com - February 3 at 12:36 AM
	Nabriva Therapeutics Announces Retirement of its Chief Financial Officer - Seite 2 wallstreet-online.de - February 1 at 6:41 PM
	Nabriva Therapeutics Announces Retirement of its Chief Financial Officer finance.yahoo.com - February 1 at 6:41 PM
	Nabriva Gets Initial Nod For $3M Investor Settlement law360.com - January 29 at 5:34 PM

Date	Company	Brokerage	Action
3/10/2021	Arbutus Biopharma	B. Riley	Lower Price Target
3/10/2021	Arbutus Biopharma	HC Wainwright	Reiterated Rating
2/25/2021	Arbutus Biopharma	Jefferies Financial Group	Initiated Coverage
11/16/2020	Arbutus Biopharma	Chardan Capital	Reiterated Rating
7/27/2020	Arbutus Biopharma	JMP Securities	Initiated Coverage
7/24/2020	Arbutus Biopharma	Robert W. Baird	Downgrade
5/19/2020	Arbutus Biopharma	Wedbush	Upgrade
10/4/2019	Arbutus Biopharma	Echelon Wealth Partners	Downgrade
12/16/2020	Galera Therapeutics	Credit Suisse Group	Upgrade
10/28/2020	Galera Therapeutics	Smith Barney Citigroup	Boost Price Target
12/2/2019	Galera Therapeutics	BTIG Research	Initiated Coverage
12/2/2019	Galera Therapeutics	Citigroup	Initiated Coverage
12/2/2019	Galera Therapeutics	Bank of America	Initiated Coverage
1/22/2021	Ampio Pharmaceuticals	Roth Capital	Reiterated Rating
3/12/2021	Nabriva Therapeutics	Northland Securities	Lower Price Target
4/8/2020	Nabriva Therapeutics	Needham & Company LLC	Downgrade
3/17/2020	Nabriva Therapeutics	Morgan Stanley	Downgrade
5/2/2019	Nabriva Therapeutics	Gabelli	Upgrade

(Data available from 4/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources